… Several anti-Aß immunotherapies have reached phase 3 testing, and immunotherapy is
likely to be the first test of the amyloid hypothesis of Alzheimer’s disease. Identifying antibody …

… Immunotherapy in mouse models of Alzheimer's disease by … in some patients with Alzheimer's
disease and was discontinued… models and patients with Alzheimer's disease indicates that …

The utility of vaccine strategies to treat neurodegenerative diseases such as Alzheimer's
disease (AD) may still hold promise. Both active and passive immunization strategies reduced …

Alzheimer's disease (AD) is the most common cause of dementia worldwide. In AD the normal
soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The oligomeric …

… or immunotherapy, prevention of Aβ aggregation and promotion of Aβ clearance by …
immunotherapy, and interference of the toxic response to Aβ by neurons by tau immunotherapy…

Targeting pathological tau protein in Alzheimer's disease (AD) and related tauopathies has
shown great potential in animal models. Given that tau lesions correlate better with the …

Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting
over 5 million people in the US alone. This neurological disorder is characterized by …

… On the other hand, passive immunotherapy (antibodies) is … In this review, we introduce
immunotherapeutic strategies … the perspectives and challenges of immunotherapies for AD. …

… murine models of Alzheimer's disease (AD… Immunotherapy approaches represent fascinating
ways to test the amyloid hypothesis and may offer genuine opportunities to modify disease …

… Immunotherapy represents one of the first tests of the amyloid hypothesis in the clinic, and
is … of Alzheimer's disease that offers a genuine opportunity to modify disease progression. …